米国の大動脈腸骨閉塞性疾患治療市場：市場規模・シェア・動向分析 (機器の種類別、処置別、最終用途別)、セグメント別予測 (2025年～2030年)

市場規模と動向：

米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療の市場規模は2024年に7億1,660万米ドルと推定され、2025年から2030年にかけてCAGR 5.4％で成長すると予測されます。

PAD罹患率の増加、政府のイニシアチブの高まり、技術の進歩が市場成長の原動力となっています。例えば、フィリップスは2024年11月、レーザーアテレクトミーと血管内結石破砕術を組み合わせた新しいハイブリッドカテーテルシステムを評価するTHOR IDE臨床試験を米国で開始しました。

この装置は、PADや大動脈-腸骨疾患によくみられる重度の石灰化病変を治療するために設計されています。ルイジアナ州のCardiovascular Institute of the Southで初めて成功した患者の処置は、この装置が複雑なインターベンションを合理化し、処置の結果を改善する可能性を示しています。政府のイニシアチブの高まりが市場成長の原動力2023年6月に発表されたCongress.Govの記事によると、米国政府は動脈・静脈包括的（ARC）法の導入により、大動脈腸骨閉塞性疾患の主な原因である末梢動脈疾患（PAD）の早期発見と管理の強化に向けて重要な一歩を踏み出しました。この法律は社会保障法の改正を提案するもので、高リスクと認定されたメディケアおよびメディケイドの受給者が、自己負担なしでPAD検診を受けられるようにすることを目的としています。

対象となる診断法には、足関節上腕血圧比（ABI）検査と動脈デュプレックススキャンが含まれ、これらはPADを特定し、大動脈-腸骨領域の疾患の重症度を評価するために重要です。2024年から2028年まで毎年600万米ドルの資金を認可するARC法は、早期診断と時宜を得た介入を改善し、進行した閉塞性疾患の負担を軽減し、腸骨ステント留置術や血行再建療法などの標的治療オプションの需要を高める可能性を追求しています。このイニシアチブは予防医療を促進し、必要不可欠な血管医療サービスへの幅広いアクセスを支援するものです。

外来手術センター（ASC）やOBL（Office-based Lab）の米国全土への普及は、大動脈腸骨閉塞性疾患を含む血管インターベンションの手技件数の増加に大きく寄与しています。このような施設は、従来の病院施設に代わる費用対効果の高い便利な選択肢を提供し、患者を迅速に治療し、諸経費を削減し、患者と医師の双方にとって柔軟なスケジューリングを可能にしています。その結果、バルーン血管形成術、ステント留置術、アテレクトミーなどの腸骨動脈インターベンションは、特に早期から中等度の病期の患者に対して、ASCやOBLで行われることが多くなってきています。これらの低侵襲手技はしばしば外来で行うことができ、回復時間の短縮と手技リスクの低減が優先されるこれらの施設に適しています。このようなセンターへのシフトは、有利な診療報酬政策にも支えられており、医療提供者や支払者にとって好ましい治療場所となっています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：機器の種類別の推定・動向分析

• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：ダッシュボード、機器の種類別
• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：変動分析、機器の種類別
• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：収益、機器の種類別
• 血管内デバイス
  • バルーン血管形成術用デバイス
  • アテローム切除システム
  • ステント
• 外科用機器

第5章 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：処置別の推定・動向分析

• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：ダッシュボード、処置別
• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：変動分析、処置別
• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：収益、処置別
• 血管内手術
  • バルーン血管形成術
  • 一次ステント留置術
  • キッシングステント
  • カバー付きステントグラフト
  • 血管内大動脈修復術（EVAR）
• ハイブリッド手術
• 外科手術

第6章 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：最終用途別の推定・動向分析

• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：ダッシュボード、最終用途別
• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：変動分析、最終用途別
• 米国の大動脈腸骨閉塞性疾患（腸骨疾患）治療市場：収益、最終用途別
• 病院
• 外来施設
• その他

第7章 競合情勢

• 主要メーカーによる最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア分析（2024年）
• 企業プロファイル
  • BD
  • Abbott
  • Boston Scientific Corporation
  • WL Gore &Associates, Inc.
  • Medtronic
  • Cook
  • Terumo Corporation
  • Getinge AB

List of Tables

• Table 1 List of Abbreviations
• Table 2 List of secondary sources
• Table 3 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by device type, 2018 - 2030 (USD Million)
• Table 4 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by procedure, 2018 - 2030 (USD Million)
• Table 5 U.S. aorto-iliac occlusive disease (iliac disease) treatment market, by end use, 2018 - 2030 (USD Million)
• Table 6 Participant's overview
• Table 7 Financial performance
• Table 8 Key companies undergoing expansions
• Table 9 Key companies undergoing acquisitions
• Table 10 Key companies undergoing collaborations
• Table 11 Key companies launching new services
• Table 12 Key companies undergoing partnerships
• Table 13 Key companies undertaking other strategies

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Market formulation & validation
• Fig. 6 U.S. aorto-iliac occlusive disease (iliac disease) treatment market segmentation
• Fig. 7 Market snapshot, 2024
• Fig. 8 Market trends & outlook
• Fig. 9 Market driver relevance analysis (current & future impact)
• Fig. 10 Market restraint relevance analysis (current & future impact)
• Fig. 11 Swot analysis, by factor (political & legal, economic, and technological)
• Fig. 12 Porter's five forces analysis
• Fig. 13 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Device Type Outlook Key Takeaways
• Fig. 14 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Device Type Movement Analysis
• Fig. 15 Endovascular devices market, 2018 - 2030 (USD Million)
• Fig. 16 Balloon angioplasty devices market, 2018 - 2030 (USD Million)
• Fig. 17 Atherectomy systems market, 2018 - 2030 (USD Million)
• Fig. 18 Stents market, 2018 - 2030 (USD Million)
• Fig. 19 Self-expanding stents market, 2018 - 2030 (USD Million)
• Fig. 20 Balloon-expandable stents market, 2018 - 2030 (USD Million)
• Fig. 21 Covered stent grafts market, 2018 - 2030 (USD Million)
• Fig. 22 Bifurcated aortic stent grafts market, 2018 - 2030 (USD Million)
• Fig. 23 Surgical devices market, 2018 - 2030 (USD Million)
• Fig. 24 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Procedure outlook key takeaways
• Fig. 25 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: Procedure movement analysis
• Fig. 26 Endovascular procedures market, 2018 - 2030 (USD Million)
• Fig. 27 Balloon angioplasty market, 2018 - 2030 (USD Million)
• Fig. 28 Primary stenting market, 2018 - 2030 (USD Million)
• Fig. 29 Kissing stents market, 2018 - 2030 (USD Million)
• Fig. 30 Covered stent grafts market, 2018 - 2030 (USD Million)
• Fig. 31 Endovascular aortic repair (EVAR) market, 2018 - 2030 (USD Million)
• Fig. 32 Hybrid procedures market, 2018 - 2030 (USD Million)
• Fig. 33 Open surgical procedures market, 2018 - 2030 (USD Million)
• Fig. 34 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: End Use outlook key takeaways
• Fig. 35 U.S. aorto-iliac occlusive disease (iliac disease) treatment market: End Use movement analysis
• Fig. 36 Hospitals market, 2018 - 2030 (USD Million)
• Fig. 37 Outpatient facilities market, 2018 - 2030 (USD Million)
• Fig. 38 Others market, 2018 - 2030 (USD Million)
• Fig. 39 Strategy framework

Market Size & Trends:

The U.S. aorto-iliac occlusive disease (iliac disease) treatment market size was estimated at USD 716.6 million in 2024 and is projected to grow at a CAGR of 5.4% from 2025 to 2030. Increasing PAD incidence, rising government initiatives, and technological advancements drive market growth. For instance, in November 2024, Philips recently launched the THOR IDE clinical trial in the U.S. to evaluate a novel hybrid catheter system that combines laser atherectomy and intravascular lithotripsy.

The device is designed to treat severely calcified lesions commonly found in PAD and aorto-iliac disease. The first successful patient procedure, conducted at the Cardiovascular Institute of the South in Louisiana, demonstrates the potential for this device to streamline complex interventions and improve procedural outcomes. Increasing government initiatives drive market growth. According to the Congress.Gov article published in June 2023, the U.S. government took a significant step toward enhancing early detection and management of Peripheral Artery Disease (PAD), a primary contributor to Aorto-Iliac Occlusive Disease, through the introduction of the Arterial and Venous Comprehensive (ARC) Act. This legislation proposes amendments to the Social Security Act, aiming to ensure that Medicare and Medicaid beneficiaries identified as high-risk can access PAD screening without incurring out-of-pocket costs.

Covered diagnostic procedures include ankle-brachial index (ABI) tests and arterial duplex scans, which are critical for identifying PAD and assessing disease severity in the aorto-iliac region. Authorizing USD 6 million in annual funding from 2024 to 2028, the ARC Act seeks to improve early diagnosis and timely intervention, potentially reducing the burden of advanced occlusive conditions and boosting the demand for targeted treatment options such as iliac stenting and revascularization therapies. This initiative promotes preventive care and supports broader access to essential vascular health services.

The proliferation of ambulatory surgical centers (ASCs) and office-based labs (OBLs) across the U.S. significantly contributes to the growth in procedural volumes for vascular interventions, including those for aorto-iliac occlusive disease. These facilities offer a cost-effective and convenient alternative to traditional hospital settings, enabling quicker patient turnaround, reduced overhead costs, and enhanced scheduling flexibility for both patients and physicians. As a result, iliac artery interventions-such as balloon angioplasty, stenting, and atherectomy are increasingly being performed in ASCs and OBLs, especially for patients presenting with early to moderate stages of the disease. These minimally invasive procedures can often be completed on an outpatient basis, making them well-suited to these settings where shorter recovery times and lower procedural risk are prioritized. The shift toward these centers is also supported by favorable reimbursement policies, making them a preferred site of care for providers and payers.

U.S. Aorto-iliac Occlusive Disease Treatment Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aorto-iliac occlusive disease (iliac disease) treatment market report based on device type, procedure, and end-use:

• Device Type Outlook (Revenue, USD Million, 2018 - 2030)
• Endovascular Devices
  • Balloon Angioplasty Devices
  • Atherectomy Systems
  • Stents
  • Self-Expanding Stents
  • Balloon-Expandable Stents
  • Covered Stent Grafts
  • Bifurcated Aortic Stent Grafts
• Surgical Devices
• Procedure Outlook (Revenue, USD Million, 2018 - 2030)
• Endovascular Procedures
  • Balloon Angioplasty
  • Primary Stenting
  • Kissing Stents
  • Covered Stent Grafts
  • Endovascular Aortic Repair (EVAR)
• Hybrid Procedures
• Open Surgical Procedures
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Outpatient Facilities
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Device Type
  • 1.2.2. Procedure
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Volume price analysis (Model 1)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Device Type outlook
  • 2.2.2. Procedure outlook
  • 2.2.3. End Use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of peripheral artery disease (PAD)
    • 3.2.1.2. Advancements in endovascular technologies
    • 3.2.1.3. Shift towards in minimally invasive procedures
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Product recalls
    • 3.2.2.2. Clinical complexity and procedural risks
• 3.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Estimates & Trend Analysis

• 4.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Dashboard
• 4.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Movement Analysis
• 4.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Device Type, Revenue
• 4.4. Endovascular Devices
  • 4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.4.2. Balloon Angioplasty Devices
    • 4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.4.3. Atherectomy Systems
    • 4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.4.4. Stents
    • 4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.4.2. Self-expanding Stents
      • 4.4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.4.3. Balloon-expandable Stents
      • 4.4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.4.4. Covered stent grafts
      • 4.4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.4.4.5. Bifurcated aortic stent grafts
      • 4.4.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
• 4.5. Surgical Devices
  • 4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Estimates & Trend Analysis

• 5.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Dashboard
• 5.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Movement Analysis
• 5.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Procedure, Revenue
• 5.4. Endovascular Procedures
  • 5.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.2. Balloon Angioplasty
    • 5.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.3. Primary Stenting
    • 5.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.4. Kissing Stents
    • 5.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.5. Covered Stent Grafts
    • 5.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.6. Endovascular Aortic Repair (EVAR)
    • 5.4.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
• 5.5. Hybrid Procedures
  • 5.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
• 5.6. Surgical Procedures
  • 5.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Estimates & Trend Analysis

• 6.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Dashboard
• 6.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Movement Analysis
• 6.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by End Use, Revenue
• 6.4. Hospitals
  • 6.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
• 6.5. Outpatient Facilities
  • 6.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company market share analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. BD
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Abbott
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Boston Scientific Corporation
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. W. L. Gore & Associates, Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Medtronic
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Cook
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Terumo Corporation
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Getinge AB
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives